Satellite Symposia

Location: Terrace 150

• Provider: Pharmacy Times Continuing Education
• Supported by: Genentech, a member of the Roche Group.
• Continuing education: Pharmacists, managed care
• Contact hours: 1.5

Program Description:

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) significantly impact vision and patient quality of life. Intravitreal administration of VEGF inhibitors has been the standard for treating retinal diseases, and while effective, these therapies may be a bit burdensome for patients due to the need for frequent injections and monitoring. New and emerging treatment options may help reduce treatment limitations, and clinical emphasis has been on improving patient adherence to treatment plans through the development of longer-lasting therapies. Managed care professionals play a vital role in the treatment selection process for patients with these conditions by optimizing drug formularies and ensuring access to care while minimizing costs. This session will review the challenges of treating nAMD and DME and the potential benefits of new treatment options. With the growing number of treatment options for patients with nAMD and DME, decision-making is more complex and requires managed care professionals to carefully consider benefits, risks, and patient goals. 

Learning Objectives:

• Identify the unmet needs as well as the disease and treatment burden for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
• Examine the latest efficacy, safety, and real-world data of treatments for nAMD and DME, including anti- ascular endothelial growth factor agents agents and emerging therapies
• Explore the value of patient-centered strategies to optimize care and reduce costs in patients with nAMD and DME  
  
  
  

Program Manager: 
Kylie Ferrentino 
Pharmacy Times Continuing Education 
kferrentino@pharmacytimes.com

Register Now

Location: Terrace 151

• Provider: CME Outfitters, LLC
• Supported by: This activity is supported by an educational grant from Lilly
• Continuing education: Managed care professionals including physicians and pharmacists, payers, pharmacy benefit managers, and clinicians within integrated delivery systems (IDSs)
• Contact hours: 1.5

Program Description:

The wide-ranging clinical practice gaps and unmet needs in ulcerative colitis (UC) management—notably, significant delays in the authorization of essential treatments, the economic implications of disease management, and the rapid evolution of treatment options—highlight a landscape fraught with challenges that directly impact patient care and outcomes. Delays in treatment initiation due to prior authorization processes not only exacerbate the risk of severe complications but also contribute to increased health care utilization and costs. Despite potential improved patient outcomes and quality of life (QoL), the introduction of novel therapies for UC adds layers of complexity to treatment decisions. Managed care professionals are at the frontline of navigating these challenges, tasked with making informed, cost-effective decisions that align with the latest evidence-based practices. The symposium will feature a diverse panel of experts discussing optimizing patient outcomes, minimizing health care costs, and effectively managing the evolving therapeutic landscape of UC.

Learning Objectives:

• Identify how delays in diagnosis and treatment initiation negatively impact patient outcomes in UC.
• Evaluate the economic consequences of suboptimal treatment in patients with moderate-to-severe UC.
• Incorporate the latest data and guidelines for the treatment of UC into population health decisions. 
  
  

Program Manager: 
Amanda Sherrod 
CME Outfitters, LLC 
sherroda@ceconcepts.com

Register Now

Location: Terrace 152

• Provider: Impact Education, LLC
• Supported by: Regeneron Pharmaceuticals, Inc.
• Continuing education: The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, specialty pharmacists, oncology pharmacists, medical directors, members of the AMCP, and other managed health care professionals attending AMCP Nexus
• Contact hours: 1.5

Program Description:

Attendees will receive enhanced knowledge and skills regarding evidence-based coverage and reimbursement policies that are based on current clinical practice guidelines for relapsed/refractory multiple myeloma, the evidence for the use of novel agents, and the factors that must be weighed in treatment selection. Additional focus will be on how plans can benefit by leveraging the full potential of multidisciplinary care in the optimal management of relapsed/refractory multiple myeloma.

Learning Objectives:

• Describe current evidence-based recommendations for the assessment and treatment of relapsed/refractory multiple myeloma (RRMM)
• Assess current and emerging agents for the treatment of RRMM based on efficacy, safety, and prior lines of therapy
• Outline the sequencing options for RRMM treatments to support the development of drug formularies and treatment algorithms
• Outline the key componets of multidisciplinary care for improving outcomes in RRMM 
  
  
  

Program Manager: 
Allison Hartless 
Impact Education, LLC 
allison.hartless@impactedu.net

Register Now

Location: Terrace 153

• Provider: Medscape Education 
• Supported by: Bristol Myers Squibb     
• Continuing education: This educational activity is primarily intended for an audience of managed care pharmacy stakeholders (pharmacists, payers, pharmacy benefit managers and others) and extended to other healthcare providers managing schizophrenia including those in psychiatry.     
• Contact hours: 1.5     

Program Description:

Join us for a 60-minute live symposium, featuring expert faculty who will discuss the challenges encountered by care decision-makers in optimizing patient outcomes when managing schizophrenia symptoms. How do treatments with innovative mechanisms of action impact patients’ quality of life, treatment-related adverse events, comorbidities, and adherence? These topics will be highlighted during the experts’ dynamic conversation, followed by a Q&A session.       

Learning Objectives:

Upon completion of this activity, participants will: 

Have increased knowledge regarding the 

• Economic burden of schizophrenia based on currently available treatment paradigms and their limitations  
• Impact on untreated/poorly treated schizophrenia patients, including the burden of residual symptoms   
• Evidence for new/emerging schizophrenia treatments 

Have greater competence related to 

• Evaluating the roles of managed care providers in improving schizophrenia outcomes 

Demonstrate greater confidence in their ability to 

• Recognize where new/emerging treatments may fit into schizophrenia care

Manager, Program Management  
Vikki Graham 
Medscape 
vchavis@medscapelive.com

Register Now

Location: Terrace 151

• Provider:  Postgraduate Healthcare Education, LLC
• Supported by: American Regent
• Continuing education: This activity is designed to meet the educational needs of managed care, specialty, and hospital/health-system pharmacists nationwide.
• Contact Hours: 1.5

Program Description:

A comprehensive educational symposium designed for pharmacists addressing the identification and management of iron deficiency (ID) in patients with heart failure (HF). Despite its prevalence, ID often goes unrecognized in HF patients, impacting their quality of life and outcomes. This program fills critical knowledge gaps by elucidating the distinct nature of ID in HF, highlighting the importance of screening and diagnosis, and detailing evidence-based treatment strategies, including the use of intravenous (IV) iron formulations. Pharmacists will also gain insights into their pivotal role in HF patient care, from screening to dosage and administration of IV iron, empowering them to optimize treatment outcomes and bridge practice gaps effectively.  

Learning Objectives:

• Explain the association between iron deficiency (ID) and heart failure (HF), including onset, clinical presentation, and criteria for diagnosis.
• Identify challenges that hinder the diagnosis and initiation of appropriate treatment of ID in HF.
• Discuss guideline recommendations for the use of intravenous (IV) iron therapy for patients for HF.
• Analyze key research studies supporting the selection and dosing of IV iron therapy in patients with HF.
• Formulate approaches for individualizing management of ID in HF, including dosage and administration strategies for IV iron therapy. 
  
  

Program Manager: 
Robin Carrino 
Postgraduate Healthcare Education, LLC 
rcarrino@postgradhealthed.com

Location: Terrace 153

• Provider:  Medscape Education
• Supported by: Abbott Diabetes Care     
• Continuing education: This activity is intended for managed care pharmacists and other managed care professionals.         
• Contact hours: 1.5

 

Program Description:

The use of diabetes devices can help people with type 2 diabetes (T2D) reach glycemic goals, yet the use remains largely suboptimal. Are you up to date on current recommendations for T2D diabetes monitoring and management, including standards of care and Healthcare Effectiveness Data and Information Set (HEDIS) measures? Join us during this live 60-minute certified symposium and interact with our 3 expert faculty by participating in case studies, submitting questions, and using real-time polling to learn how you can improve health care for all people with T2D. Register to reserve your spot!      

Learning Objectives:

Upon completion of this activity, participants will:

Have increased knowledge regarding the

• Updated quality metrics related to successful diabetes management 
• Updates in the role of automated insulin delivery (AID) and continuous ketone monitoring (CKM) in patients with diabetes from a payer perspective
• New data supporting the role and use of continuous glucose monitoring (CGM) in patients with T2D 

Demonstrate greater confidence in their ability to

• Appreciate the value of new technologies for diabetes assessment and monitoring 

Manager, Program Management 
Vikki Graham 
Medscape 
vchavis@medscapelive.com

Register Now

Location: Terrace 151

• Provider: CME Outfitters, LLC
• Supported by: Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
• Continuing Education: Managed care professionals including physician medical directors and pharmacists
• Contact hours: 1.5

Program Description:

In this CME Outfitters live symposium, expert faculty will address biomarker testing in community oncology settings and its impact on treatment selection and patient outcomes, particularly in underserved patient populations. Education is needed on available biomarker testing strategies in prostate, bladder, and lung cancer to improve management of patients. Factors that contribute to health inequities include clinician unconscious biases, systemic barriers, patient social drivers of health, and lack of best practice models for access to equitable cancer care. Education will address these barriers and provide best practices to improve biomarker testing strategies and access to appropriate therapeutic decision-making. 

Learning Objectives:

• Evaluate the latest biomarker testing strategies in prostate, bladder, and lung cancer, including their impact on treatment decision-making.
• Integrate all members of the care team in strategies to provide equitable biomarker testing in community oncology settings.
• Identify the root causes of health inequity in cancer care.
• Incorporate action-oriented strategies to address unconscious bias and patient SDoH in cancer care management.

Program Manager: 
Shannon Boorstein 
CME Outfitters, LLC 
Boorsteins@cmeoutfitters.com

Register Now

Location: Terrace 150

• Provider: Pharmacy Times Continuing Education
• Supported by: Genentech, a member of the Roche Group
• Continuing education: Pharmacists, managed care
• Contact hours: 1.5

 

Program Description:

People with food allergies need to be vigilant about avoiding their allergens, but this often causes increased stress about safe food options and the availability of rescue medications in case of accidental exposures. These current approaches for the management of severe food-related reactions have their limitations. Ongoing research is targeting both novel immunomodulators and biologic therapy to improve patients' desensitization and tolerance to food allergens and reduce severe reactions. Several organizations have released guidelines for the management of food allergies, and managed care professionals and pharmacists must work to implement their recommendations in clinical practice. Evolving approaches in food allergy management, from strict allergen avoidance to the evolving use of immunomodulators and targeted biologics will be reviewed. Managed care pharmacists should follow these developments as new treatment options become available for patients with food allergies and use key policy recommendations to update protocols and formularies to improve health-related quality of life and outcomes for patients living with food allergies. 

Learning Objectives:

• Analyze the economic and treatment burden associated with managing food allergies, considering direct and indirect costs, health care system strain, and the impact on families
• Examine the clinical and real-world data for new and emerging agents targeting immunoglobulin E in food allergies and their potential to mitigate symptoms and improve patient outcomes
• Investigate managed care strategies designed to facilitate appropriate access to effective food allergy treatments, considering cost-effectiveness, coverage policies, and improving patient outcomes

Program Manager: 
Kylie Ferrentino 
Pharmacy Times Continuing Education 
kferrentino@pharmacytimes.com

Register Now

 

Location: Terrace 152

• Provider: HMP Education
• Supported by: Lilly USA, LLC
• Continuing education: This activity is intended for pharmacy directors, medical directors, and other decision makers working in managed care organizations (MCOs) such as private payers, pharmacy benefit managers, Medicare/Medicaid, Veterans’ Affairs/Department of Defense (VA/DoD), large employers, hospitals, accountable care organizations (ACOs), long-term care, and clinicians in other segments, as well as hospital and health-system pharmacists, clinical pharmacists, specialty pharmacists, and community pharmacists.
• Contact hours: 1.5

 

Program Description:

The global prevalence of Alzheimer’s Disease (AD) has steadily increased over the past three decades and the societal burdens of the disease are expected to remain substantial for decades to come. While traditional therapies for symptoms of AD (eg, cholinesterase inhibitors, memantine, antipsychotics) cannot slow, stop, or reverse the underlying disease process, several amyloid-Beta targeting therapies (ATTs) have shown potential to become disease-modifying therapies (DMTs) in early AD. Expert faculty will lead this 90-minute symposium focused on ATTs for patients with early AD. Video interviews incorporated throughout the session will highlight the lived experience of those diagnosed with early AD and consequent navigation of this disease. Participants will gain a greater understanding of how novel ATTs work to slow the progression of AD, how to optimize treatment in patients receiving these ATTs and minimize costly adverse effects and treatment nonadherence, and how to best practice shared decision-making to improve AD care and outcomes. Case-based faculty discussions, learner polling, and a robust Q&A session will enhance the learner experience.  

Learning Objectives:

• Assess the economic burden, impact on patients/caregivers, and unmet needs associated with AD

• Describe the value of early AD diagnosis and treatment

• Evaluate the efficacy/safety data and administration considerations of available/emerging amyloid-beta targeting therapies for early AD

• Apply evidence-based guidelines and recommendations for the timely identification, mitigation, and management of adverse events associated with amyloid-beta targeting therapies

• Implement managed care strategies to balance treatment efficacy and best practices with cost-effectiveness for optimal outcomes in patients with AD

Program Manager: 
Kristin Ciszeski 
HMP Education 
kciszeski@hmpglobal.com

Diane Borges 
HMP Education 
dborges@hmpglobal.com

Register Now